Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Kathmere Capital Management LLC

Kathmere Capital Management LLC increased its position in Amgen Inc. (NASDAQ:AMGN) by 10.7% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,895 shares of the medical research company’s stock after purchasing an additional 280 shares during the period. Kathmere Capital Management LLC’s holdings in Amgen were worth $905,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Strategic Financial Concepts LLC bought a new stake in shares of Amgen in the 2nd quarter valued at approximately $26,000. Horizon Financial Services LLC bought a new stake in Amgen during the first quarter valued at $28,000. United Community Bank acquired a new stake in shares of Amgen during the fourth quarter worth $29,000. nVerses Capital LLC bought a new position in shares of Amgen in the 2nd quarter worth about $31,000. Finally, Bbjs Financial Advisors LLC acquired a new position in shares of Amgen in the 2nd quarter valued at about $33,000. 76.50% of the stock is owned by institutional investors.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $322.67 on Friday. Amgen Inc. has a twelve month low of $249.70 and a twelve month high of $346.85. The company has a current ratio of 1.26, a quick ratio of 0.89 and a debt-to-equity ratio of 9.64. The firm has a 50-day moving average of $328.77 and a two-hundred day moving average of $307.33. The company has a market capitalization of $173.09 billion, a price-to-earnings ratio of 46.10, a PEG ratio of 2.98 and a beta of 0.61.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.01 by ($0.04). The business had revenue of $8.39 billion during the quarter, compared to analyst estimates of $8.35 billion. Amgen had a return on equity of 161.72% and a net margin of 10.12%. The company’s quarterly revenue was up 20.1% compared to the same quarter last year. During the same quarter last year, the firm posted $5.00 EPS. As a group, analysts expect that Amgen Inc. will post 19.49 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, August 6th. Investors of record on Friday, August 16th were paid a $2.25 dividend. The ex-dividend date was Friday, August 16th. This represents a $9.00 dividend on an annualized basis and a yield of 2.79%. Amgen’s dividend payout ratio is currently 128.57%.

Wall Street Analysts Forecast Growth

AMGN has been the topic of several research reports. Royal Bank of Canada reiterated an “outperform” rating and set a $362.00 price objective on shares of Amgen in a research note on Thursday. Bank of America raised their price target on Amgen from $325.00 to $330.00 and gave the stock a “neutral” rating in a report on Wednesday, August 7th. TD Cowen upped their price objective on Amgen from $360.00 to $381.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Cantor Fitzgerald assumed coverage on Amgen in a research note on Friday. They issued an “overweight” rating and a $405.00 target price on the stock. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $305.00 price target (down previously from $310.00) on shares of Amgen in a report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Amgen has an average rating of “Moderate Buy” and an average price target of $325.55.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.